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Abstract
Preoperative staging of breast cancer based on breast imaging is mandatory. Breast imaging 
encompasses mammography, breast sonography and MR-mammography. Earlier diag-
nosis of breast cancer results in a favourable oncological outcome. Limitations and influ-
ences on operative procedures of MR-mammography in diagnosis and staging of breast 
cancer have to be discussed. Different interventional procedures have been developed. 
The histological results of interventional procedures guided by ultrasound, stereotactic 
mammography or magnetic resonance have to be integrated in planning surgical resec-
tion margins in oncoplastic breast-conserving surgery. Image-guided wire markings are 
an important tool for planning these surgical resection margins. This chapter summarises 
the results of breast imaging, interventional procedures and wire markings for the breast-
conserving therapy of breast cancer. Breast imaging and interventional procedures are 
the basis for a concept of targeted oncoplastic breast surgery.
Keywords: breast cancer, breast imaging, mammography, breast ultrasound, magnetic 
resonance mammography, oncoplastic surgery, interventional breast diagnostics
1. Breast imaging
Earlier diagnosis of breast cancer results in a favourable outcome. Tumour size at diagnosis 
and the lymph node stage are the best predictive factors of outcome. As a result, the current 
strategy for reducing breast cancer mortality is to diagnose the disease as early as possible. 
Breast imaging is fundamental for the early diagnosis of breast cancer when symptoms occur 
or during screening programs.
Breast imaging is a general term that encompasses mammography, breast sonography, breast 
magnetic resonance imaging (MRI) and other technologies. To provide uniformity in the 
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assessment of breast imaging findings, the American College of Radiologists (ACR) estab-
lished final assessment classifications [Breast Imaging Reporting and Data System (BI-RADS)] 
[1–3]. The final assessment categories are as follows: BI-RADS 1, negative; BI-RADS 2, benign; 
BI-RADS 3, probably benign (risk of malignancy <2%); BI-RADS 4, suspicious abnormality 
(biopsy should be considered); BI-RADS 5, highly suggestive of malignancy.
BI-RADS 4 and 5 assessments indicate abnormalities that require tissue biopsy for diagnosis. 
These categories represent a wide range (3–100%) of breast cancer risk.
2. Mammography
Mammography has been the basis of breast imaging for more than 30 years. The sensitivity 
of mammography for breast cancer is age dependent. The denser the breast, the less effective 
this method is for detecting early signs of breast cancer. In younger women, breast density 
tends to be higher, and increased density inhibits the detection of early signs of breast can-
cer [4]. The sensitivity of mammography for breast cancer in women over 60 years of age is 
about 95%, while mammography can be expected to detect less than 50% of breast cancers in 
women under 40 years of age [5]. Mammography is based on X-rays. Consensus is that the 
benefits of mammography in women over the age of 40 years are likely to far outweigh any 
oncogenic effects of repeated exposure. Screening of women over the age of 50 by mammog-
raphy is accepted practice. However, in symptomatic patients with a palpable nodule in the 
breast, there is even an indication for performing mammography in women under the age 
of 35 when there is a strong clinical suspicion of malignancy. Practice is changing, and ultra-
sound is being increasingly used for the assessment of women with focal breast symptoms in 
this age range. Mammography is performed every 2 years in all women in the screening age 
group (50 years of age – 69 years of age) attending symptomatic patients who have not had 
a screening mammogram in the past year. Film/screen mammography has been refined over 
the years and has now reached the limits of this technology [6]. Film/screen mammography is 
a difficult technique to maintain at the quality levels required for optimal diagnosis because 
labour-intensive quality control measures are necessary to maintain the diagnostic standards. 
Today, digital mammography is the new standard. Major benefits have been predicted from 
acquiring mammograms in a direct digital format [7]. Compared with conventional mam-
mography, the predicted benefits of full-field digital mammography include better imaging 
of the dense breast, the application of computer-aided detection and a number of logistical 
advantages providing potential for more efficient mammography services. The much wider 
dynamic range of digital mammography means that visualization of the entire breast density 
range on a single image is easily achievable. In the clinical setting, comparative studies have 
shown that digital mammography performs as well as film/screen mammography [8–11].
Recent preoperative mammographic evaluation is necessary to determine patient’s eligibil-
ity for breast-conserving therapy. Mammography defines the extent of a patient’s disease, 
the presence or absence of multicentricity and other factors (extent of microcalcifications) 
that might influence the treatment decision, and evaluates the contralateral breast. If the 
mass is associated with microcalcifications, an assessment of the extent of the calcifications 
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is performed. Magnification mammography is important for further characterisation of 
microcalcifications.
Mammography is the basis for stereotactic-guided breast biopsy. Stereotactic biopsy can be 
carried out using a prone biopsy table or by using an add-on device to a conventional upright 
mammography unit. This technique is used for biopsy of clinically occult lesions that are not 
detectable by ultrasound (e.g. microcalcifications) [12].
3. Ultrasound
High-frequency (≥7.5 MHz) ultrasound is a very effective diagnostic tool for the investigation 
of focal breast symptoms. It has a high sensitivity for breast lesions and also a very high nega-
tive predictive value. High-resolution ultrasound easily distinguishes between most solid 
and cystic lesions and can differentiate benign from malignant lesions with a high accuracy. 
Ultrasound is the technique of choice for the further investigation of focal symptomatic breast 
lesions at all ages. Under 35 years of age, when the risk of breast cancer is very low, it is usu-
ally the preferred imaging technique. Over 35 years of age, when the risk of breast cancer 
begins to increase, it is often used in conjunction with mammography. Ultrasound is less 
sensitive than mammography for the early signs of breast cancer and is therefore not used 
for population-based screening. However, ultrasound increases the detection of small breast 
cancer in women with a dense background tissue on mammography [13–15]. In the screening 
setting, there is currently insufficient evidence of any mortality benefit even in women with 
dense mammograms. Ultrasound is the preferred technique to guide biopsy of both palpable 
and impalpable breast lesions visible on scanning [16]. Ultrasound is being increasingly used 
to assess the axilla in women with breast cancer. Axillary nodes that show abnormal morphol-
ogy can be accurately sampled by needle core biopsy.
Doppler ultrasound adds additional accuracy to breast diagnosis and is widely used. Three-
dimensional ultrasound of the breast also increases the accuracy of biopsy and the detection 
of multifocal disease but is not widely available [17, 18]. Elastography is a new application 
of ultrasound technology that allows the accurate assessment of the stiffness of the breast 
tissue. It is being evaluated at present and may prove to be a useful tool in excluding sig-
nificant abnormalities, for instance, in assessment of asymptomatic abnormalities detected 
by ultrasound.
4. Magnetic resonance mammography
Magnetic resonance imaging (MRI) is widely available and used in breast cancer diagnosis. 
Magnetic resonance mammography (MRM) requires dedicated breast coils. In order to image 
the breast, the patient is scanned prone, and injection of intravenous contrast (Gd-DTPA) is 
required. A variety of possible clinical indications for contrast-enhanced MRM have been 
reported. These include screening for breast cancer, determining the local extent of malignant 
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disease, identifying an occult primary, assessing response to neoadjuvant chemotherapy, 
identifying local recurrences after breast-conserving therapy, breast imaging after implant 
reconstruction or breast augmentation, and the detection of ipsilateral breast cancer in patients 
presented with axillary lymph node metastases (CUP-syndrome) [19–23].
MRM is the most sensitive technique for detection of breast cancer, approaching 100% for 
invasive cancer and 60–70% for ductal carcinoma in situ (DCIS), but it has a high false-positive 
rate [24–28]. Rapid acquisition of images facilitates assessment of signal enhancement curves 
that can be helpful in distinguishing benign and malignant disease. Breast lesions seen on 
MRM that are larger than 10 mm can be seen on ultrasound if they are clinically significant 
(second-look ultrasound). MRM is likely to prove the best method for screening younger 
women (under 40 years) at increased risk of breast cancer but it is unlikely to be used for 
general population screening. MRM is the best technique for imaging women with breast 
implants. It is also of benefit in identifying recurrent breast cancer after breast-conserving 
therapy where conventional imaging has failed to exclude recurrence. Performed more than 
12 months after surgery, MRM will accurately distinguish between tumour recurrence and 
scars [29, 30]. MRM is being increasingly used to examine women for multifocal or multicen-
tric disease prior to conservation surgery, especially in patients with invasive lobular breast 
cancer. MRI of the axilla will demonstrate axillary metastatic disease but its sensitivity is not 
sufficient for it to replace surgical staging of the axilla.
Many questions surrounding the use of MRM of the breast in patients with breast cancer 
remain unanswered. Just because MRM can detect additional areas of cancer, does it really 
matter clinically? Should surgical treatment be altered because MRM detects additional 
foci of cancer, especially in those cases when these areas represent foci of DCIS? Would 
these additional areas of cancer identified on MRM be successfully treated with postopera-
tive radiation therapy? The rate of MRM-detected multifocal disease, which ranges from 
16–37%, is clearly much higher than the rate of in-breast recurrence after breast-conserving 
therapy, with reported rates in two studies with a 20-year follow-up of 8.8% and 14.3%, 
respectively [31, 32]. This strongly suggests that in some, and perhaps many cases, the 
additional foci of cancer identified only on MRM, especially those that prove to be in situ 
disease, would likely be successfully treated with postoperative radiation. Which MRM-
detected multifocal or multicentric cancer would be successfully treated with postoperative 
radiation and which would not, later presenting as a local “recurrence”? In those cases 
when MRM detects an invasive cancer that is clearly separate from the primary cancer, 
either in the same or a different quadrant, should mastectomy be recommended, based on 
the historical treatment of clinically or mammographically detected multifocal or multicen-
tric cancer, or is the patient still eligible for breast-conserving therapy if the lesion can be 
successfully excised with negative margins [33]? There are additional questions concerning 
patient selection. Which are the patients at the highest risk for having multifocal or mul-
ticentric cancer who would benefit most from MRM (young patients, patients with dense 
breasts, patients with lobular cancer)? Based on the current success of breast-conserving 
surgery, it is unlikely that MRM of the breast is warranted in all patients with newly diag-
nosed breast cancer [20, 34]. Clinical investigation continues in an effort to find answers to 
these questions (Figure 1).
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5. Breast cancer screening
The aim of breast cancer screening is to reduce mortality through early detection. Randomised 
controlled trials and case–control studies demonstrated that population screening by mam-
mography can be expected to reduce overall breast cancer mortality by around 25%. [35, 36]. 
The validity of these trials was questioned, but subsequent reviews have reaffirmed the mor-
tality benefit of mammographic screening and determined that criticisms of the mammo-
graphic screening trials were unjustified [37, 38]. The mortality benefit of screening is greatest 
in women aged 50–70 years. Screening of women under the age of 40 has not been shown to 
provide any mortality benefit [39–41].
Figure 1. Complementary breast imaging.
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The screening method is two-view mammography. Clinical examination of the breast and 
breast self-examination have not been shown to contribute to mortality reduction through 
early detection.
Women at increased risk of developing breast cancer due to a proven inherited predisposing 
genetic mutation, family history, previous radiotherapy or benign risk lesions may be selected 
for screening at young age [42, 43]. There is evidence that MRM is the most sensitive method of 
imaging young women [44]. The specificity of MRM is low and the rate of false-positive results 
is high—these circumstances have been extensively discussed. Second-look and targeted ultra-
sound and preoperative MRI-guided biopsy can increase the low specificity of MRM.
6. Image-guided breast biopsy
Needle biopsy is highly accurate in determining the nature of most breast lesions classified 
as BI-RADS 4 or 5. Patients with benign conditions avoid unnecessary surgery. Carrying out 
open surgical biopsy for diagnosis should be regarded as a failure of the diagnostic process. 
For patients who prove to have breast cancer, needle biopsy provides accurate understanding 
of the type and extent of disease, so ensuring that patients and the doctors treating them are 
able to make informed treatment choice. Needle biopsy not only provides information on the 
nature of malignant disease, such as histological type and grade, but also enables pretreat-
ment analyses of prognostic and predictive factors to characterise the immunohistochemical 
phenotype and the tumour biology (hormone-receptors, HER-2 receptor, genetic profiling, 
etc.) [45, 46].
Breast needle biopsies of nonpalpable lesions require imaging to guide needle placement. 
Imaging guidance can be performed with ultrasonography, stereotactic mammography or 
MRM. Ultrasound guidance is the technique of choice; it is less costly and easy to perform. 
Ultrasound provides real-time visualisation of the biopsy procedure and visual confirmation 
of adequate sampling. Between 80 and 90% of breast abnormalities will be clearly visible on 
ultrasound [47]. For impalpable abnormalities not visible on ultrasound, stereotactic-guided 
biopsy is required. A few lesions are only visible on MRM and require magnetic resonance-
guided biopsy.
Most lesions selected for ultrasound-guided biopsy are solid masses that can be sampled 
with 14-gauge core needles. The technical aspects involved in performing ultrasound-guided 
procedures with a free-hand approach have been described previously [48]. The technique 
used consists of the following steps: imaging the lesion, finding the needle in the longitudinal 
plane through the breast, maximally visualising the needle tip and placing the needle in the 
lesion. Development of good hand-eye coordination is crucial to a successful lesion sampling 
(Figure 2) [49].
Using the 14-gauge needle, multiple core biopsy samples are necessary to ensure accurate 
sampling of different areas of the lesion. In most cases, accurate lesion sampling can be 
achieved by obtaining 3–5 core samples for masses and 5–10 core samples for microcalcifica-
tions [50, 51].
Breast Imaging72
To improve sampling of microcalcifications using digital, stereotactic mammography guid-
ance, the vacuum-assisted biopsy instrument with probes coming in 11-gauge size has been 
developed [12]. In contrast to the automated biopsy gun devices, the directional, vacuum-
assisted biopsy instrument is inserted once and rotated while in the breast to obtain samples 
from different areas of the lesion. A vacuum is used to pull tissue samples into the sam-
ple notch, where it is cut and transported back through the needle and out to the collection 
chamber. Multiple tissue samples are collected without removing the needle from the breast 
(Figure 3).
Studies have shown improved sampling of microcalcifications with the vacuum-assisted 
biopsy instrument [52, 53]. For calcifications, it is imperative that there is a proof of  representative 
Figure 2. US-guided breast core biopsy (14-gauge).
Figure 3. Vacuum-assisted core biopsy (11-gauge).
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sampling with specimen radiography. If calcification is not demonstrated on the specimen 
radiography and the histology is benign, then management cannot be based on this result as 
there is a high risk of sampling error; the procedure must either be repeated or open surgical 
biopsy carried out [54–60].
An 8-gauge vacuum-assisted biopsy probe is preferred for therapeutic removal of breast 
lesions such as fibroadenomas [61–64].
The low specificity of MRM requires the ability to perform MRI-guided biopsies, which 
require an additional specialised MRI biopsy coil and MRI-compatible wires and needles 
for localisation and core biopsies [65–67]. Centres that cannot perform MRI-guided localisa-
tion and biopsy lack the ability to manage lesions visible only with MRI and are at a clear 
disadvantage.
The technical aspects of MRI-guided localisation and biopsy are similar to those for ste-
reotactic biopsies in that the patient is prone during the procedure, the breast is held in 
compression, and the needle plane is guided into the tissue parallel to the chest wall. Needle 
placement is performed with the patient outside the bore of the magnet using an MRI-
compatible needle, often made of titanium. The patient is then returned to the magnet, and 
confirmation of adequate needle placement is obtained. After sufficient core samples are 
obtained outside of the bore of the magnet, a clip is placed marking the biopsy cavity. In our 
practice, patients with MRM-detected indeterminate or suspect lesions are first scheduled 
for targeted second-look ultrasonography because often these lesions can be visualised after 
discovery on MRM.
In cases of complete radiological removal of small occult breast lesions with needle biopsies, 
clip marking with the possibility for re-localisation in cases of necessary therapeutic open 
surgical resection is mandatory. Core needle and vacuum-assisted biopsy is extremely useful 
in the evaluation of patients with multiple suspect lesions.
It is important that the result of needle breast biopsy is always correlated with the clinical 
and imaging findings before clinical management is discussed with the patient. This is best 
achieved by reviewing each case at prospective multidisciplinary meetings. The results of 
image-guided breast biopsies are translated in the planning process of targeted oncoplastic 
breast surgery when malignancy is diagnosed. Breast surgery is directly based on breast imag-
ing and interventional diagnosis. Multidisciplinary coworking between radiology, pathology 
and breast surgery is mandatory.
7. Wire-guided surgical excision
The number of impalpable, clinically occult breast lesions is increasing. Accurate localisation 
techniques are required to facilitate their surgical excision as the therapeutic part of a planned 
oncoplastic breast-conserving procedure [68]. The hooked wire is the most commonly 
employed technique and has proved very reliable. There are various designs of localisation 
wire in common use. All have some form of anchoring device such as a hook with a splayed 
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or barbed tip. The wire is placed under ultrasound, stereotactic or MRI guidance (for MRM 
lesions only) within a rigid over-sheath cannula, which is then removed once positioning is 
satisfactory. Most wires are very flexible, and when the cannula is removed, the wire may 
assume a quite circuitous course. Care must be taken to avoid displacing the wire.
Procedures that can be surgically more challenging are wide local excisions (segmental resec-
tion) for DCIS with no mass lesion. In such cases, where the distribution of disease is often 
more eccentric, careful three-dimensional excision planning especially in oncoplastic proce-
dures is necessary. Inserting more than one wire and even bracketing and framing the lesion 
with two or three can occasionally be useful (Figure 4).
If the procedure is being performed to establish a diagnosis (diagnostic segmentectomy), a rep-
resentative portion of the lesion is excised through a small incision, thus leaving a  satisfactory 
Figure 4. Wire-guided (mammography and MRI) segmental excision.
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cosmetic result if the lesion proves to be benign. In the therapeutic situation, the marked 
lesion should be completely excised. Intraoperative specimen radiography is essential, both 
to check that the lesion has been removed and, if cancer has been diagnosed, to ensure that 
adequate radiological resection margins have been achieved. We have to consider that espe-
cially in DCIS, the proved radiological resection margin (specimen radiography) sometimes 
differs from the histological resection margin [68–71].
8. Translation of breast imaging into targeted breast surgery
Advances in breast imaging have led some to question whether whole-breast ultrasound or 
MRM should be part of the standard preoperative evaluation of a patient with breast cancer. 
Golshan et al. [72] reviewed the impact of ipsilateral whole-breast ultrasound on the surgical 
management of 426 patients with clinical stage I and II cancer. Seventy-five of the 426 patients 
(18%) had additional lesions identified by ultrasound, but only 12 were malignant. The role 
of ultrasound as a diagnostic tool for the evaluation of breast masses is well established (as 
is its role in defining lesions that are poorly seen on mammogram or are mammographically 
occult), and the available data support its use as a routine tool when evaluating patients for 
breast-conserving therapy.
Tillmann et al. [73] reported the results of a similar study of the impact of MRM on the 
management of 207 women with DCIS and stage I and II breast cancer. The MRM find-
ings affected clinical management in 20% of cases. In 6%, MRM had an unfavourable effect 
due to false-positive findings that resulted in unnecessary mastectomy or additional breast 
biopsies.
The work of Holland et al. [33] indicated that microscopic foci of invasive and non-invasive 
cancer are present at a distance from apparently localised primary tumours in a signifi-
cant number of patients. Only 39% of specimens showed no evidence of cancer beyond the 
reference tumour, while in 20%, additional cancer was found within 2 cm of the reference 
tumour. Forty-one per cent of patients had residual cancer more than 2 cm from the refer-
ence tumour. The percentage of patients with residual cancer more than 2 cm from the refer-
ence tumour corresponds well to the rate of local recurrences reported in patients treated 
with breast-conserving surgery alone without postoperative radiotherapy. Radiotherapy is 
effective in controlling the majority of these occult foci of carcinoma.
The ability of MRM and ultrasound to identify these tumour foci raises the possibility that 
significant numbers of women who could be treated with breast-conserving therapy will be 
subject to unnecessary mastectomy. Histologic subtype other than invasive ductal carcinoma 
does not appear to be associated with an increased risk of recurrence. If the tumour is not 
diffuse in the breast and can be completely excised with negative margins, patients with inva-
sive lobular carcinoma are candidates for breast-conserving therapy. However, because of 
the increased incidence of multicentricity, invasive lobular cancer associated with increased 
mammographic density is an accepted indication for preoperative MRM before breast- 
conserving therapy.
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9. Conclusion
The translation of breast imaging, interventional procedures and wire-guided surgical exci-
sion into a concept of targeted oncoplastic breast-conserving surgery is mandatory, and an 
interdisciplinary task for the breast radiologist and the breast surgeon to achieve the best 
oncological and aesthetic outcomes for patients with breast cancer is also mandatory.
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